Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

ClinicalTrials.gov ID: NCT04002115

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04002115. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Clofarabine Pre-conditioning Followed by Hematopoietic Stem Cell Transplant With Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Investigators would like to study the incidence of complete remission (CR) at day +30 after Clofarabine followed by haploidentical transplant. The conditioning regimen used is Fludarabine, Busulfan (2 doses) or cyclophosphamide (2 doses) and Total Body Irradiation (TBI) with post transplant cyclophosphamide for patients with Acute Myeloid Leukemia (AML) who are not in remission prior to considering allogeneic transplant with haploidentical donors.

Study identification

NCT ID: NCT04002115
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Milton S. Hershey Medical Center; Other
Enrollment: 2 participants

Conditions and interventions

Conditions

Acute Myeloid Leukemia

Interventions

Clofarabine Drug
Fludarabine Drug
Busulfan Drug
Total Body Irradiation (TBI) Procedure
Cyclophosphamide Drug
Granulocyte Colony-Stimulating Factor Drug
Tacrolimus Drug
Cellcept Drug

Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 3, 2020 (Actual)
Primary completion: Aug 30, 2022 (Actual)
Completion: Nov 7, 2022 (Actual)
Last update posted: Sep 14, 2023

2020 – 2022

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Penn State Cancer Institute	Hershey	Pennsylvania	17033	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04002115, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 14, 2023 · Synced Nov 12, 2026